| Abstract: |
"The [phase 1b/2] data [are] promising and support the current phase 3, multicenter trial, which we hope will lead to FDA approval and a new muchneeded treatment option for this patient population," said David Sallman, MD. Combination treatment with eprenetapopt (APR246) and azacitidine is welltolerated, yielding high rates of clinical response and molecular remissions among patients with TP53mutant myelodysplastic syndrome (MDS) and oligoblastic acute myeloid leukemia (AML), according to a phase 1b/2 study (NCT03072043) published in the Journal of Clinical Oncology.1 "Patients with TP53mutant disease, which is roughly 10% to 20% of AML and de novo MDS cases, don't... |
